Press release
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% SANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE,
About this update from Si-bone, Inc.
[{"type":"text","content":"Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%\nSANTA CLARA, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2025. Fourth Quarter 2025 Summary (any comparisons are to the prior year period) Worldwide revenue between $56.2 - $56.3 million, representing ~15% growthU.S. revenue between $53.3 - $53.4 million, representing ~14% growth~1,640 active physicians in the U.S., an increase of 250 physicians, representing ~18% growthCash and equivalents of ~$147.7 million, implying net cash generation of ~$2.0 million in the quarter Fiscal Year 2025 Summary (any comparisons are to the prior year period) Worldwide revenue between $200.8 - $200.9 million, representing ~20% growthU.S. revenue between $190.9 - $191.0 million, representing ~21% growth The fourth quarter and full year 2025 revenue and cash and equivalents are included in this release on a preliminary basis, prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment. SI-BONE expects to provide fourth quarter and full year 2025 financial results during its fourth quarter 2025 earnings call in late February 2026. About SI-BONE, Inc.SI-BONE (NASDAQ: SIBN) is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 200 peer reviewed publications. For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com. SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved. Forward Looking Statements The statements in this press release regarding expectat...